Capsule Summary Slidesets

Share

Program Content

Activities

  • ARV-110 in mCRPC
    Phase I Study of Proteolysis-Targeting Chimera Degrader ARV-110 in Metastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • IMvigor010: Adjuvant Atezo
    Phase III IMvigor010: Adjuvant Atezolizumab vs Observation in Patients With High-Risk Muscle-Invasive Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • KEYNOTE-426: Pembro + Axi in RCC
    Phase III KEYNOTE-426: Updated Analysis of First-line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 02, 2020

    Expires: June 01, 2021

  • SAVOIR
    SAVOIR: Savolitinib vs Sunitinib in MET-Driven Papillary Renal Cell Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • FRACTION-RCC: Nivo + Ipi
    Phase II FRACTION-RCC Adaptive Design Trial: Nivolumab + Ipilimumab in Advanced RCC Progressing After Checkpoint Inhibitor Therapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • CheckMate 214 Biomarkers
    CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

  • RCC: Anti–PD-1 Efficacy Markers
    Immunogenomic Determinants of Response and Survival to PD-1 Blockade in Advanced Clear Cell RCC
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 08, 2020

    Expires: June 07, 2021

  • COSMIC-021 Cohort 2
    COSMIC-021 Cohort 2 Expansion: Phase Ib Study of Cabozantinib Plus Atezolizumab in Urothelial Carcinoma After Prior Platinum Chemotherapy
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 01, 2020

    Expires: May 31, 2021

  • EV-103: Enfortumab Vedotin Plus Pembro
    EV-103: Phase I/II Trial of Enfortumab Vedotin Plus Pembrolizumab in Patients With Locally Advanced/Metastatic Urothelial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • ICI & Antibiotics in UC
    Timing of Antibiotic Use During Immune Checkpoint Inhibitor Therapy and Clinical Outcomes in Patients With Urothelial Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 05, 2020

    Expires: June 04, 2021

  • ARAMIS Final Analysis
    ARAMIS Final Analysis: OS With Darolutamide Plus ADT vs Placebo Plus ADT for Nonmetastatic Castration-Resistant Prostate Cancer
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 04, 2020

    Expires: June 03, 2021

  • JAVELIN Bladder 100
    JAVELIN Bladder 100: Phase III Trial of Maintenance Avelumab After First-line Platinum Chemotherapy in Advanced Urothelial Carcinoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: June 03, 2020

    Expires: June 02, 2021

Provided by

ProCE Banner

Supporters

AbbVie Inc.

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Jazz Pharmaceuticals

Karyopharm Therapeutics

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer and EMD Serono